CD3E and neoplasm: As with the deletion of PTPN2 in T cells, we found that the systemic administration of Compound 182 and the repression of AT3-OVA tumor growth also increased p-STAT-1 staining within the tumor, as well as the abundance of CD3ε+ T cells (Fig. 7g).